Conformationally restricted tricyclic analogues of lipophilic pyrido[2, 3-d]pyrimidine antifolates [1a, b]

Aleem Gangjee, Farahnaz Mavandadi, Sherry F. Queener

Research output: Contribution to journalArticle

1 Scopus citations


The effect of conformational restriction of the C9-N10 bridge on inhibitory potency and selectivity of trimetrexate against dihydrofolate reductase, was studied. Specifically three nonclassical tricyclic 1, 3-diamino-8-(3′, 4′, 5′-trimethoxybenzyl)-7, 9-dihydro- pyrrolo[3, 4-c]pyrido[2, 3-d]pyrimidin-6(5H, 8H)-one (4), 1, 3-diamino-8-(3′, 4′, 5′-trimethoxybenzyl)-9-hydro-pyrrolo [3, 4-c]pyrido[2, 3-d]pyrimidin-6-(8H)-one (5) and 1, 3-diamino-(8H)-(3′, 4′, 5′-trimethoxybenzyl)-7, 9-dihydro- pyrrolo[3, 4-c]pyrido[2, 3-d]pyrimidine (7) antifolates were synthesized. The tricyclic analogues 4 and 5 were obtained via the regiospecific cyclo-condensation of the β-keto ester 17 with 2, 4, 6-triaminopyrimidine. The analogue 7 was obtained via reduction of the lactam 4 with borane in tetrahydrofuran. Compounds 4, 5 and 7 were evaluated as inhibitors of dihydrofolate reductase from Pneumocystis carinii, Toxoplasma gondii and rat liven All three compounds were more selective than trimetrexate against Pneumocystis carinii dihydrofolate reductase and significantly more selective than trimetrexate against Toxoplasma gondii dihydrofolate reductase compared with rat liver dihydrofolate reductase.

Original languageEnglish (US)
Pages (from-to)213-220
Number of pages8
JournalJournal of Heterocyclic Chemistry
Issue number1
StatePublished - Jan 1 2001


ASJC Scopus subject areas

  • Organic Chemistry

Cite this